Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Peritoneal Neoplasms × talimogene laherparepvec × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 7 Breast Neoplasms 3 Triple Negative Breast Neoplasms 2 Sarcoma 2 Carcinoma, Merkel Cell 2 Squamous Cell Carcinoma of Head and Neck 1 Peritoneal Neoplasms 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, T-Cell, Cutaneous 1 Colorectal Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Hepatocellular 1 Carcinoma, Ductal, Breast 1 Carcinoma, Ductal 1 Carcinoma, Basal Cell 1 Advanced Non CNS Tumors 1 Adenocarcinoma 1

Interventions

Paclitaxel 14 Cisplatin 12 Carboplatin 11 Cytoreduction Surgical Procedures 9 Oxaliplatin 8 Hyperthermic Intraperitoneal Chemotherapy 8 Fluorouracil 7 Bevacizumab 6 Doxorubicin 5 Leucovorin 4 Gemcitabine 4 catumaxomab 3 nintedanib 2 liposomal doxorubicin 2 Surgical Procedures, Operative 2 Palliative Care 2 Mitomycin 2 Drug Therapy 2 Docetaxel 2 Blood Specimen Collection 2 Albumin-Bound Paclitaxel 2 130-nm albumin-bound paclitaxel 2 veliparib 1 tremelimumab 1 talimogene laherparepvec 1 strattice 1 sodium thiosulfate 1 poly(I).poly(c12,U) 1 phenoxodiol 1 lentiviral minigene vaccine of COVID-19 coronavirus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03663712 2024-11-20

TEMPO

Duke University

Phase 1 Completed

28 enrolled 10 charts

Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡